Drugs in ATC Class R06AB

Up to Top Level ATC Classes

Up to R - Respiratory system

Up to R06 - ANTIHISTAMINES FOR SYSTEMIC USE

Up to R06A - ANTIHISTAMINES FOR SYSTEMIC USE

Drugs in ATC Class: R06AB - Substituted alkylamines

Tradename	Generic Name
BROMANATE DM	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
BROMFED-DM	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
BROMPHENIRAMINE MALEATE	brompheniramine maleate
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
DIMETANE	brompheniramine maleate
DIMETANE-TEN	brompheniramine maleate
DRIXORAL PLUS	acetaminophen; dexbrompheniramine maleate; pseudoephedrine sulfate

R06AB Market Analysis and Financial Projection

The ATC Class R06AB - Substituted Alkylamines encompasses antihistamines with alkylamine-derived structures, such as brompheniramine, dexchlorpheniramine, and chlorphenamine. These drugs are primarily used to treat allergic conditions by blocking H1 histamine receptors. Below is an analysis of their market dynamics and patent landscape:

---

Market Dynamics

Growth Drivers

1. Rising Allergy Prevalence:

   • Increasing global cases of allergic rhinitis, urticaria, and dermatitis drive demand[11][14][15].
   • Urbanization, pollution, and climate change exacerbate allergy rates, particularly in Asia-Pacific[11][14].

2. Cost-Effectiveness:

   • Substituted alkylamines like brompheniramine remain popular due to affordability, especially in low- and middle-income countries[11][16].

3. Product Innovation:

   • Non-sedative formulations and combination therapies (e.g., R06AB51 brompheniramine combinations) cater to evolving patient needs[1][7].

4. OTC Accessibility:

   • Over-the-counter availability in many regions enhances consumer access, though reimbursement changes (e.g., Germany’s 2004 GMG law) have shifted market dynamics[6][11].

Market Size and Projections

• The global antihistamine market was valued at \$263.9 billion in 2022, with a projected CAGR of 8.6% to reach \$647.7 billion by 2033[11].
• H-1 blockers, including substituted alkylamines, dominate product segments with 58.3% market share (2023)[14].

Regional Trends

• North America: Leads with 35.8% market share (2023), driven by advanced healthcare infrastructure and high allergy prevalence[14].
• Asia-Pacific: Fastest-growing region due to population growth and increasing allergy awareness, particularly in China and India[11][15].

---

Patent Landscape

Key Patents and Innovations

1. Synthesis Methods:

   • Patents like US6576796B1 and EP1026163A1 describe processes for producing alkylamines and derivatives, highlighting ongoing R&D in manufacturing efficiency[9][12].
   • CZ303356B6 covers novel substituted alkylamine derivatives for therapeutic use[5].

2. Drug Formulations:

   • Brompheniramine’s synthesis was patented in the 1950s (US Patent 2,567,245), but generics now dominate[7].
   • Recent patents focus on combination therapies (e.g., R06AB51) and extended-release formulations[1][3].

Challenges

• Generic Competition: Most substituted alkylamines are off-patent, leading to price erosion and market fragmentation[11][16].
• Regulatory Shifts: Stricter OTC reimbursement policies in Europe have impacted sales volumes[6][15].

---

Competitive Landscape

• Major Players: Bayer AG, Sanofi, Teva Pharmaceuticals, and Sun Pharma leverage economies of scale to compete in generic markets[11][15].
• Emerging Markets: Companies like Glenmark Pharmaceuticals (India) focus on localized formulations (e.g., Ryaltris-AZ nasal spray)[11].

---

Future Outlook

• Opportunities:
  • Development of dual-action therapies (antihistamine + corticosteroid) to address complex allergies[11][15].
  • Expansion in Asia-Pacific and RoW regions with unmet medical needs[10][15].
• Threats:
  • Regulatory hurdles for new combinations[6].
  • Shift toward second-generation antihistamines (e.g., cetirizine) with fewer side effects[14][15].

---

Highlight: "The global alkylamines market is projected to grow at a CAGR of 6.5%, driven by demand in solvents, agrochemicals, and pharmaceuticals"[10].

Key Takeaways

• Substituted alkylamines remain vital in allergy management but face competition from newer agents.
• Patent activity focuses on synthesis optimization and combo products, while generics dominate sales.
• Market growth hinges on Asia-Pacific expansion and innovation in drug delivery systems.

References

1. https://www.wikidoc.org/index.php/ATC_code_R06
2. https://pubchem.ncbi.nlm.nih.gov/compound/Brompheniramine
3. https://atcddd.fhi.no/atc_ddd_index/?code=R06AB&showdescription=no
4. https://atcddd.fhi.no/atc_ddd_index/?code=R06AB
5. https://patents.google.com/patent/CZ303356B6/en
6. https://www.bast.de/EN/Traffic_Safety/Subjects/Druid/deliverales-list/downloads/Deliverable_2_1_1.pdf?__blob=publicationFile&v=1
7. https://go.drugbank.com/drugs/DB00835
8. https://en.wikipedia.org/wiki/ATC_code_R06
9. https://patents.google.com/patent/US6576796B1/en
10. https://www.marketsandmarkets.com/Market-Reports/alkylamines-market-726.html
11. https://www.futuremarketinsights.com/reports/antihistamine-market
12. https://patents.google.com/patent/EP1026163A1/en
13. https://patents.google.com/patent/US2194314A/en
14. https://market.us/report/antihistamines-market/
15. https://www.researchandmarkets.com/reports/4620282/antihistamines-market-size-market-share
16. https://list.essentialmeds.org/files/trs/KmctuAAMtPBorqeQRged3u44S6eeGKQPvOfhGr65.pdf